Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 7/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 6/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150861 | 1.00 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2POLBALDH1A1 | |
| SCHEMBL12860287 | 1.00 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2POLBALDH1A1 | |
| SCHEMBL12860251 | 0.94 | TAS1R3 (0.35) | TAS1R3TAS1R1TAS1R2HTR2C | |
| SCHEMBL12860189 | 0.94 | TAS1R3 (0.35) | TAS1R3TAS1R1TAS1R2HTR2C | |
| SCHEMBL1151040 | 0.94 | TAS1R3 (0.35) | TAS1R3TAS1R1TAS1R2HTR2C | |
| SCHEMBL12860302 | 0.88 | TAS1R3 (0.36) | TAS1R3TAS1R1TAS1R2ALDH1A1HTT | |
| SCHEMBL1151156 | 0.88 | USP2 (0.39) | TAS1R3TAS1R1TAS1R2POLBHTT | |
| SCHEMBL1151015 | 0.88 | TAS1R3 (0.36) | TAS1R3TAS1R1TAS1R2ALDH1A1HTT | |
| SCHEMBL12860170 | 0.88 | TAS1R3 (0.36) | TAS1R3TAS1R1TAS1R2ALDH1A1HTT | |
| SCHEMBL12860276 | 0.88 | USP2 (0.39) | TAS1R3TAS1R1TAS1R2POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884244-B2 | Therapeutic fluoroethylcyano guanidines | ALLERGAN, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884244-B2 | Therapeutic fluoroethylcyano guanidines | ALLERGAN, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | PDE3A, PDE2A, PDE3B | TAS1R3 3072/4885TAS1R1 3294/4885TAS1R2 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.